Financial Performance Forecast - The company expects a net profit attributable to shareholders of the parent company for 2024 to be between 543.97 million and 652.76 million yuan, representing a year-on-year increase of 38% to 65%[3] - The net profit attributable to shareholders of the parent company, excluding non-recurring gains and losses, is expected to be between 517.74 million and 621.28 million yuan, reflecting a year-on-year increase of 59% to 91%[3] - The previous year's net profit attributable to shareholders of the parent company was 395.26 million yuan, with a total profit of 650.54 million yuan[5] - There are no significant uncertainties affecting the accuracy of the performance forecast[8] - The forecast data is preliminary and the final financial data will be disclosed in the official 2024 annual report[9] Operational Improvements - The company has optimized its sales organization and business model, transitioning from a heavy distribution model to a focus on terminal promotion, enhancing product competitiveness[7] - The company has implemented refined operational management and deepened market cultivation for key products, leading to improved gross margins[7] Government Support - The company received a repayment of 78.27 million yuan from the Harbin Municipal Government, which contributed positively to the current period's profit[7]
哈药股份(600664) - 2024 Q4 - 年度业绩预告